1. Accurate Diagnosis and Treatment of Patients With Thrombotic Microangiopathy

2. Program Goals

3. Overview

4. What is Thrombotic Microangiopathy (TMA)?

5. Different TMAs Have Different Etiologies and Require Different Management Approaches

6. In aHUS, Complement Dysregulation Leads to Chronic, Uncontrolled Complement Activation

7. Establishing an Accurate TMA Diagnosis

8. aHUS Can Be Unmasked by Complement-Amplifying Conditions

9. Patient #1: Introduction

10. Patient #1: Additional Laboratory Data

11. Patient #1: Initial Treatment

12. Patient #1: Ongoing Management

13. Patient #1: Follow-Up

14. Patient #2: Introduction

15. Patient #2: Laboratory Findings

16. Patient #2: Clinical Course

17. Patient #2: Management

18. Plasma Exchange/Plasma Infusion (PE/PI) and TMA

19. PE/PI Fails to Inhibit Chronic Uncontrolled Activation of the Complement System in Patients With aHUS[a,b]

20. PE/PI Does Not Resolve Deteriorating Renal Function in Patients With Ongoing aHUSa

21. Patients With TMA Treated with PE/PI: Those With ADAMTS13 Activity >5% Have Increased Rates of ESRD and Premature Mortalitya

22. PE/PI Failed to Improve Graft Survival in Patients With aHUS After Kidney Transplantationa

23. Summary

24. Abbreviations

25. Abbreviations (cont)

26. References

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)